PRFX — PainReform Income Statement
0.000.00%
Last trade - 00:00- $3.80m
- $0.32m
- 18
- 81
- 33
- 39
Annual income statement for PainReform, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 1.67 | 7.21 | 8.87 | 9.58 | 14.7 |
| Operating Profit | -1.67 | -7.21 | -8.87 | -9.58 | -14.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.83 | -7.24 | -8.78 | -9.34 | -14.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.05 | -7.25 | -8.79 | -9.34 | -14.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.05 | -7.25 | -8.79 | -9.34 | -14.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.05 | -7.25 | -8.79 | -9.34 | -14.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -111 | -177 | -198 | -171 | -32.2 |